journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research

journal
https://www.readbyqxmd.com/read/28407516/quantitative-mir-analysis-in-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-proliferation-centres-are-characterized-by-high-mir-92a-and-mir-155-and-low-mir-150-expression
#1
Kinga Szurián, Irén Csala, Violetta Piurkó, Linda Deák, András Matolcsy, Lilla Reiniger
Proliferation centres (PCs) are histological hallmarks of lymph nodes in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). Chromosomal abnormalities have already been described to accumulate preferably in the PCs as opposed to the intervening small cell areas. To further characterize the pathogenic role of PCs, the expression levels of 17 selected miRs known to be involved in the development of CLL/SLL were compared in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL...
April 4, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28407515/high-cd200-expression-is-associated-with-poor-prognosis-in-cytogenetically-normal-acute-myeloid-leukemia-even-in-flt3-itd-npm1-patients
#2
Mario Tiribelli, Donatella Raspadori, Antonella Geromin, Margherita Cavallin, Santina Sirianni, Erica Simeone, Monica Bocchia, Renato Fanin, Daniela Damiani
Overexpression of CD200, a trans-membrane protein belonging to the immunoglobulin superfamily, has been associated with poor prognosis in patients with acute myeloid leukemia (AML). As few data are available in the subset of cytogenetically-normal (CN) AML, we retrospectively evaluated the correlations between CD200 expression and response to therapy in a series of 139 adults with CN-AML. CD200 was expressed in 67/139 (48%) cases; 18 of them (28%) expressed CD200 at high intensity. No differences in CD200 expression rate were observed according to age, WBC count, type of leukemia, FLT3 or NMP1 mutation, and CD56 expression...
April 4, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28376405/dna-methyltransferase-1-mediated-aberrant-methylation-and-silencing-of-shp-1-gene-in-chronic-myelogenous-leukemia-cells
#3
Yinghua Li, Xuedong Liu, Xiufeng Guo, Xiao Liu, Jianmin Luo
INTRODUCTION: Extensive studies on SHP-1 protein and SHP-1 mRNA revealed that the diminishment or abolishment of the expression of SHP-1 in leukemias/lymphomas was due to aberrant promoter methylation. Thus far, the mechanism of epigenetic silencing of the SHP-1 tyrosine phosphatase gene that occurs in chronic myelogenous leukemia cells remains poorly understood. METHODS: The expressions of the target molecules were determined by quantitative real time PCR and western blot, respectively...
March 25, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28380402/the-role-of-thrombocytapheresis-in-the-contemporary-management-of-hyperthrombocytosis-in-myeloproliferative-neoplasms-a-case-based-review
#4
REVIEW
Prajwal Boddu, Lorenzo Falchi, Chitra Hosing, Kate Newberry, Prithviraj Bose, Srdan Verstovsek
Extreme thrombocytosis induces an acquired thrombotic-hemorrhagic diathesis, and left uncontrolled is a harbinger of potentially fatal vascular complications. Currently, cytoreduction with medical therapy remains the mainstay of hyperthrombocytosis management. However, it offers a less-than-ideal option in situations where a rapid reduction in platelets is urgently needed, as in the presence of vital end-organ ischemia or to ameliorate of life-threatening hemorrhage. The role of thrombocytapheresis, or plateletpheresis, in hyperthrombocytosis has become increasingly obsolete given the proactive titration of cytoreductive therapies and early identification and correction of reversible causes of reactive thrombocytosis...
March 22, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28380403/5-triphosphate-sirna-targeting-mdr1-reverses-multi-drug-resistance-and-activates-rig-i-induced-immune-stimulatory-and-apoptotic-effects-against-human-myeloid-leukaemia-cells
#5
Dengzhe Li, Robert Peter Gale, Yanfeng Liu, Baoxia Lei, Yuan Wang, Dongmei Diao, Mei Zhang
Multi-drug resistance (MDR), immune suppression and decreased apoptosis are important causes of therapy-failure in leukaemia. Short interfering RNAs (siRNAs) down-regulate gene transcription, have sequence-independent immune-stimulatory effects and synergize with other anti-cancer therapies in some experimental models. We designed a siRNA targeting MDR1 with 5'-triphosphate ends (3p-siRNA-MDR1). Treatment of leukaemia cells with 3p-siRNA-MDR1 down-regulated MDR1 expression, reduced-drug resistance and induced immune and pro-apoptotic effects in drug-resistant HL-60/Adr and K562/Adr human leukaemia cell lines...
March 21, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28359030/increase-of-dna-damage-and-alteration-of-the-dna-damage-response-in-myelodysplastic-syndromes-and-acute-myeloid-leukemias
#6
Henning D Popp, Nicole Naumann, Susanne Brendel, Thomas Henzler, Christel Weiss, Wolf-Karsten Hofmann, Alice Fabarius
Increased DNA damage and alteration of the DNA damage response (DDR) are critical features of genetic instability presumably implicated in pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML). We used immunofluorescence staining of γH2AX and 53BP1 for analyzing DNA double-strand breaks (DSB) in MDS and AML cell lines, in CD34+ selected cells of normal and MDS bone marrow (including three cases of chronic myelomonocytic leukemias) and in blasts of AML bone marrow. In addition, we screened for activation of the DDR by immunoblotting of p-ATM, p-ATR, p-CHK1, p-CHK2 and p-TP53...
March 21, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28343141/survival-outcomes-in-iron-chelated-and-non-chelated-patients-with-lower-risk-myelodysplastic-syndromes-review-and-pooled-analysis-of-observational-studies
#7
EDITORIAL
Ivo Abraham, Majed Al Yami, Seongseok Yun, Hee-Ju Kim, Nicole D Vincelette, Ali McBride, Karen MacDonald
No abstract text is available yet for this article.
March 18, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28364582/clinical-relevance-of-tp53-polymorphic-genetic-variations-in-chronic-lymphocytic-leukemia
#8
Nadiia Bilous, Iryna Abramenko, Vladimir Saenko, Anatoliy Chumak, Iryna Dyagil, Zoya Martina, Iryna Kryachok
OBJECTIVES: To analyze the distribution of single nucleotide polymorphisms (SNPs) in the TP53 gene in chronic lymphocytic leukemia (CLL) patients and to evaluate their associations with clinical behavior of the disease. METHODS: SNPs in exons and parts of adjacent introns of the TP53 gene were analyzed in 235 CLL patients observed during 2005-2012 years. Data on individuals of European descent from the 1000 Genomes Project data set were used as a reference. RESULTS: In the recessive model of inheritance, we found borderline associations between CLL risk and C/C genotype of rs1642785 (p=0...
March 16, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28314441/erratum-to-higher-t-cell-imbalance-and-growth-factor-receptor-expression-in-b-cell-chronic-lymphocytic-leukemia-b-cll-as-compared-to-monoclonal-b-cell-lymphocytosis-of-undetermined-significance-b-mlus-leukemia-res-13-1-1989-31-37
#9
C Garcia, A Rosén, E Kimby, M Aguilar-Santelises, M Jondal, M Björkhilm, G Holm, H Mellstedt
No abstract text is available yet for this article.
March 14, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28324774/methylation-changes-of-sirt1-klf4-dapk1-and-spg20-in-b-lymphocytes-derived-from-follicular-and-diffuse-large-b-cell-lymphoma
#10
Raffaele Frazzi, Eleonora Zanetti, Mariaelena Pistoni, Ione Tamagnini, Riccardo Valli, Luca Braglia, Francesco Merli
Diffuse large-B cell lymphomas (DLBCL) and follicular lymphomas (FL) are the most represented subtypes among mature B-cell neoplasms and originate from malignant B lymphocytes. Methylation represents one of the major epigenetic mechanisms of gene regulation. Silent information regulator 1 (SIRT1) is a class III lysine-deacetylase playing several functions and considered to be a context-dependent tumor promoter. We present the quantitative methylation, gene expression and tissue distribution of SIRT1 and some key mediators related to lymphoma pathogenesis in B lymphocytes purified from biopsies of follicular hyperplasias, FL and DLBCL...
March 9, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28324773/haptoglobin-is-frequently-low-in-patients-with-myelofibrosis-clinical-relevance
#11
Paolo Strati, Lucia Masarova, Prithviraj Bose, Naval Daver, Naveen Pemmaraju, Srdan Verstovsek
A recent study, showing the absence of paroxysmal nocturnal hemoglobinuria clones in myelofibrosis, has reopened the debate around the role of decreased haptoglobin in this disease. We present here a large prospective analysis of the clinical significance of low haptoglobin in 152 patients with myelofibrosis. Low haptoglobin (<32mg/dL) was observed in 50 patients (33%). Decreased haptoglobin did not associate with low hemoglobin levels, positive Coombs test or abnormal liver function tests, suggesting it is not result of autoimmune hemolytic anemia or liver cirrhosis...
March 8, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28359029/is-there-immune-surveillance-against-chronic-myeloid-leukaemia-possibly-but-not-much
#12
LETTER
Robert Peter Gale, Gerhard Opelz
No abstract text is available yet for this article.
March 6, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28342362/the-only-thing-that-is-constant-is-change-the-2016-revision-to-the-world-health-organisation-classification-of-myelodysplastic-syndrome
#13
LETTER
Devendra Hiwase
No abstract text is available yet for this article.
March 6, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28288324/reversal-of-multidrug-resistance-of-leukemia-cells-is-not-necessarily-induced-by-direct-mir-138-mdr1-promoter-interaction
#14
LETTER
Javier T Granados-Riveron, Guillermo Aquino-Jarquin
No abstract text is available yet for this article.
March 6, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28288323/anti-angiogenic-and-anti-multiple-myeloma-effects-of-oprozomib-opz-alone-and-in-combination-with-pomalidomide-pom-and-or-dexamethasone-dex
#15
REVIEW
Eric Sanchez, Mingjie Li, Cathy S Wang, George Tang, Abigail Gillespie, Haiming Chen, James R Berenson
Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib. We set out to determine the anti-angiogenic effect of OPZ using the choriollantoic membrane/feather bud (CAM/FB) model and its anti-MM effects using MM xenograft models (LAGκ-1A, LAGλ-1). OPZ significantly reduced blood vessel formation, endothelial gene and protein expression using the CAM/FB assay. In vivo, we determined the anti-MM effects of OPZ, dexamethasone (Dex) and pomalidomide (Pom) and showed that the combinations of two drugs (OPZ+Dex or OPZ+Pom) showed marked anti-MM effects when compared to monotherapy...
March 6, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28340380/the-origin-and-evolution-of-the-term-clone
#16
David P Steensma
In biology, the term "clone" is most widely used to designate genetically identical cells or organisms that are asexually descended from a common progenitor. The concept of clonality in hematology-oncology has received much attention in recent years, as the advent of next-generation sequencing platforms has provided new tools for detection of clonal populations in patients, and experiments on primary cells have provided fascinating new insights into the clonal architecture of human malignancies. The term "clone" is used more loosely by the general public to mean any close or identical copy...
March 4, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28301819/mir-155-as-a-potential-target-of-il-3-signaling-in-primary-aml-cells
#17
LETTER
Teresa Sadras, Chung H Kok, Michelle Perugini, Hayley S Ramshaw, Richard J D'Andrea
miR-155 has emerged as one of the key microRNAs (miRNAs) involved in normal and malignant myelopoiesis, and high expression of this miRNA has been flagged as a strong independent prognostic marker in Acute Myeloid Leukemia (AML). While elevated expression of miR-155 has been associated with FLT3-ITD mutations, other mechanisms which may regulate expression of this miRNA in AML remain largely unknown. Here, we present new evidence that miR-155 may be a prime target of IL-3 signaling in primary AML cells. This finding, together with the increasingly apparent role for miR-155 in oncogenesis, and the upregulation of the IL-3 receptor alpha subunit in AML, lead us to propose this pathway may significantly contribute to the leukemic transformation...
March 4, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28292719/donor-age-matters-in-t-cell-depleted-haploidentical-hematopoietic-stem-cell-transplantation-in-pediatric-patients-faster-immune-reconstitution-using-younger-donors
#18
Marta González-Vicent, Blanca Molina, Natalia Deltoro, Julián Sevilla, José Luis Vicario, Ana Castillo, Manuel Ramirez, Miguel Ángel Díaz
T-cell depleted (TCD) haploidentical transplantation is increasingly used in paediatric patients with haematological malignancies and donor selection is a challenge. We conclude that a simple criterion such as donor age should be also considered in depleted haploidentical setting because faster immune reconstitution is achieved using younger donors decreasing non-relapse related mortality.
March 4, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28279876/cytomegalovirus-reactivation-is-associated-with-a-lower-rate-of-early-relapse-in-myeloid-malignancies-independent-of-in-vivo-t-cell-depletion-strategy
#19
Talal Hilal, Stacey Slone, Shawn Peterson, Charles Bodine, Zartash Gul
The association between cytomegalovirus (CMV) reactivation and relapse risk has not been evaluated in relation to T cell depletion strategies. We evaluated 93 patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and analyzed the association between T cell depletion strategies with the cumulative incidence of relapse and CMV reactivation. A total of 33% of patients who received ATG vs. 34% who received alemtuzumab developed CMV reactivation. The cumulative incidence of relapse was 3% at 1year and 20% at 3 years in patients with CMV reactivation vs...
March 1, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28324772/new-proposals-of-the-who-working-group-2016-for-the-diagnosis-of-myelodysplastic-syndromes-mds-characteristics-of-refined-mds-types
#20
Corinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, Aristoteles Giagounidis, Rainer Haas, Norbert Gattermann, John M Bennett, Carlo Aul, Ulrich Germing
Based on centrally diagnosed 3528 patients in the Düsseldorf registry, we validated the new proposals for the classification of the MDS by the WHO working group: 256 patients were diagnosed as MDSSLD (7,3%), 978 MDSMLD (27,7%), 227 MDS RS SLD (6,4%); 321 MDS RS MLD (9,1%), 159 MDS del(5q) (4,5%), 481 MDSEB 1 (13,6%), 620 MDSEB 2 (17,6%), and 148 MDS-U (4,2%). 352 patients (16,9% of the non blastic types) changed the category, mainly moving from RCMD to MDS RS MLD, RCUD and RCMD to MDS del(5q). Median survival times of the refined groups differed from more than 60 months in the MDSSLD (RS) groups, 37 months in the MDSMLD (RS) groups, 79 months of the MDS del(5q) group and 21 and 11 months in the MDSEB 1 and 2 groups, respectively...
February 27, 2017: Leukemia Research
journal
journal
27133
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"